WO2006006720A1 - γδT細胞の培養方法、γδT細胞及び治療・予防剤 - Google Patents
γδT細胞の培養方法、γδT細胞及び治療・予防剤 Download PDFInfo
- Publication number
- WO2006006720A1 WO2006006720A1 PCT/JP2005/013218 JP2005013218W WO2006006720A1 WO 2006006720 A1 WO2006006720 A1 WO 2006006720A1 JP 2005013218 W JP2005013218 W JP 2005013218W WO 2006006720 A1 WO2006006720 A1 WO 2006006720A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- acid
- concentration
- culturing
- peripheral blood
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000012258 culturing Methods 0.000 title claims abstract description 15
- 230000003449 preventive effect Effects 0.000 title claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims abstract description 153
- 229940122361 Bisphosphonate Drugs 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 23
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract description 23
- 201000011510 cancer Diseases 0.000 claims abstract description 23
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 12
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims abstract description 9
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims abstract 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- 210000002325 somatostatin-secreting cell Anatomy 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 8
- 210000000988 bone and bone Anatomy 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 150000004677 hydrates Chemical class 0.000 claims description 6
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 6
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 5
- 229960003978 pamidronic acid Drugs 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 229960004343 alendronic acid Drugs 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 4
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 229960000759 risedronic acid Drugs 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 229960004276 zoledronic acid Drugs 0.000 claims description 3
- 229960005236 ibandronic acid Drugs 0.000 claims description 2
- 229950006971 incadronic acid Drugs 0.000 claims description 2
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims description 2
- 230000004097 bone metabolism Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 abstract description 24
- 210000005259 peripheral blood Anatomy 0.000 abstract description 11
- 239000011886 peripheral blood Substances 0.000 abstract description 11
- 238000009169 immunotherapy Methods 0.000 abstract description 3
- 210000001616 monocyte Anatomy 0.000 abstract 3
- 230000008685 targeting Effects 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 230000000069 prophylactic effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- NYNKCGWJPNZJMI-UHFFFAOYSA-N Clebopride malate Chemical compound [O-]C(=O)C(O)CC(O)=O.COC1=CC(N)=C(Cl)C=C1C(=O)NC1CC[NH+](CC=2C=CC=CC=2)CC1 NYNKCGWJPNZJMI-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108091008877 NK cell receptors Proteins 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FGBXDQWECLPOGZ-UHFFFAOYSA-N [Na].O.O.O.O.O.[Na] Chemical compound [Na].O.O.O.O.O.[Na] FGBXDQWECLPOGZ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- RLIRIVMEKVNVQX-UHFFFAOYSA-L disodium;(2-cycloheptyl-1-phosphonatoethyl)-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound [Na+].[Na+].OP([O-])(=O)C(P(O)([O-])=O)CC1CCCCCC1 RLIRIVMEKVNVQX-UHFFFAOYSA-L 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
Definitions
- the present invention relates to a method for culturing ⁇ 5 ⁇ cells. Further, the present invention relates to a cultivated cell (5 ⁇ cells, a therapeutic-preventive agent containing a cell cultured by the culture method.
- cancer malignant neoplasm
- T cells there is a therapy that activates T cells called L ⁇ (1 ymp h o kine e-a c t i v a t e d k i l l e r; lymphokine-activated killer) therapy.
- L ⁇ (1 ymp h o kine e-a c t i v a t e d k i l l e r; lymphokine-activated killer
- T cells There are two types of T cells: ⁇ / 3-type TCR (T cellreceptor)] 3 T cells and ⁇ -type TCR-expressing ⁇ cells. This is a therapy that activates ⁇ cells.
- ⁇ 3 ⁇ cells are those that are mainly responsible for acquired immunity.
- ⁇ cells are cells responsible for innate immunity. Recently, it has been found that it has cytotoxic activity (non-specific activity) against cancer cells, and research on immunotherapy using the strong antitumor activity of ⁇ cells has been conducted.
- ⁇ ⁇ ⁇ cells recognize and activate non-peptidic antigens, and as a non-peptidic antigen, for example, alkylamines can be stimulated with bisphosphonates to activate and / or proliferate.
- a non-peptidic antigen for example, alkylamines can be stimulated with bisphosphonates to activate and / or proliferate.
- ⁇ cells are usually present in only 1 to 5% of peripheral blood, even if a small amount of blood is collected to activate and / or proliferate ⁇ cells, the purity and number of cells sufficient for treatment There is a problem that cannot be secured. Also treatment If the amount of blood collected from a patient is increased in order to ensure sufficient purity and cell count, there is also a problem that a great burden is placed on the patient.
- CD 56-positive cells 5T cells
- CD 56-negative cells ⁇ T cells positive ⁇ T cells are known to have higher cytotoxic activity than CD 56 negative ⁇ ⁇ cells (Fu j imiya, Y. eta 1. Clinical Cancer Re search Vo l. 3, 6 33— 643, Ap ril 1997), and is expected to be applied to the treatment of cancer and infectious diseases.
- JP-A-2001-314183 describes therapeutic agents and examples using a cell group containing 50% or more of CD56-positive cells.
- the CD56-positive cells used here are A ⁇ cells and natural killer cells (hereinafter referred to as ⁇ cells) are mixed, and only about 10% of ⁇ ⁇ 5 ⁇ cells are included. Disclosure of the invention
- the present invention has been made in view of the above circumstances, and is capable of selectively activating and cultivating or proliferating cells from peripheral blood mononuclear cells, and capable of culturing them in high purity and in large quantities. And a therapeutic / prophylactic agent containing the ⁇ ⁇ cells obtained by the method in immunotherapy for cancer patients, infectious diseases, etc. With the goal.
- the concentration of a bisphosphonate bone metabolizer (hereinafter abbreviated as bisphosphonate) in peripheral blood mononuclear cells is 0.05 to 100 / ⁇ and interleukin 2 (hereinafter IL— 2) (abbreviated as 2) is added so that the concentration is 50 to 20000 U / mL and cultured.
- bisphosphonate a bisphosphonate bone metabolizer
- IL— 2 interleukin 2
- bisphosphonate is added to peripheral blood mononuclear cells in the culture solution so as to have a concentration of 0.05 to 100 M.
- ⁇ ⁇ cells selectively activated and expanded or proliferated and further stimulated by adding IL-12 to 50-2000 U / mL. It can be obtained in high purity and in large quantities. Also got The T 6 ⁇ cells contain at least 40% of cells expressing CD 56.
- the bisphosphonate is added at the start of culture.
- ⁇ cells obtained by the present invention have a non-specific cytotoxic function, a cancer antigen-specific cytotoxic function, or both cytotoxic functions. Therefore, it can be used as a therapeutic / preventive agent for cancer diseases and infectious diseases.
- the ⁇ 5 ⁇ cell obtained by the present invention contains a large amount of CD 56-positive ⁇ ⁇ cells having a high cytotoxic function. Therefore, by selecting for CD56-positive cells, it is possible to obtain a higher therapeutic / prophylactic effect when the same number of cells are administered.
- the therapeutic / prophylactic agent prepared by the present invention has a non-specific cytotoxic function, a cancer antigen-specific cytotoxic function, or both cytotoxic functions.
- High content of r ⁇ and high cytotoxic function among r ⁇ ⁇ cells Because it contains a lot of 5 T cells, it can identify cancer cells or infected cells without attacking normal cells. It is effective in the treatment of various cancer types and infectious diseases, especially when ⁇ ⁇ cells are derived from autologous lymphocytes and are administered to the patient's own immunity. It is possible to perform its function without being excluded by the system.
- the concentration of the bisphosphonate bone metabolizing agent in the peripheral blood mononuclear cells is from 0.05 to ⁇ 10 1/1 and the concentration of IL-1 is from 50 to It is characterized by selectively activating and / or proliferating ⁇ cells by adding and culturing at 200 U / mL to obtain a cell population containing ⁇ 5 ⁇ cells with high purity. To do.
- Bisphosphonates may have any action to suppress bone resorption and are generally used as a therapeutic agent for osteoporosis.
- Examples thereof include pamidronic acid, a salt thereof and / or a hydrate thereof (eg, pamidronic acid Disodium pentahydrate (A redia, Novartis Pharma), alendronate, its salts and / or their hydrates (eg, sodium alendronate trihydrate (O ne 1 ast, ⁇ ⁇ ) Pharmaceutical)), zoledronic acid, its salts and / or their hydrates (for example, zole Sodium Dronate Hydrate (Zome ta, Novartis Pharma), Risedronic acid, its salts and Z or their hydrates (eg, risedronate sodium 'hydrate), ibandronic acid, its salts and Z or a hydrate thereof (eg, ibandronate disodium), incadronic acid, a salt thereof and Z or a hydrate thereof (eg, disodium incadronate),
- peripheral blood by collecting blood.
- the appropriate amount is 15-25 mL. If this amount can be obtained, it can be suitably cultured. However, the range is not limited to this range as long as the peripheral blood volume is sufficient at the start of culture, and the upper limit may be further increased if the burden on the donor to collect blood is small.
- peripheral blood mononuclear cells by, for example, density gradient centrifugation. About 10 to 7 peripheral blood mononuclear cells can be obtained from 15 to 25 mL of peripheral blood.
- a suspension of peripheral blood mononuclear cells is referred to as a cell suspension.
- the culture medium shown here it can be used for culturing cells such as RPMI-1640 medium (Invitrogen), Dulbecco's modified Eagle medium (Invitrogen, hereinafter referred to as DMEM), Iskov medium (Invitrogen, hereinafter referred to as IMEM), etc. You may use the commercially available culture solution used.
- serum may be added at 0.1 to 20%.
- serum for example, fetal calf serum (Feta1CalfSerum, hereinafter referred to as FCS), AB serum, autologous plasma, or the like may be used.
- IL-2 to the above culture solution at a concentration of 50 to 2000 UZmL, more preferably. Preferably, add 400 to 100 OUZmL.
- 6) with IL- 2 34 to 38 ° C were added thereto, and more preferably at 37, 2-10%, and more preferably are cultured at 5% C_ ⁇ 2 presence.
- a culture solution is appropriately added according to the number of cells to be cultured.
- the IL-12 concentration is appropriately added so as to be 50 to 200 OU / mL, more preferably 400 to LOO OUZmL.
- the culture period is 7 days or longer, a cell group containing ⁇ cells with high purity can be obtained. However, in order to further increase the number of r ⁇ cells, it is preferable to culture for about 14 days.
- the ⁇ ⁇ cells obtained in this way contain a lot of CD 56 positive ⁇ ⁇ ⁇ cells with high cytotoxic function.
- CD 56 positive ⁇ ⁇ ⁇ cells can also be selected and used. Is possible. Examples of methods for sorting CD 56-positive ⁇ cells include magnetic cell separation (Magnetic Cell Sorting, hereinafter referred to as MAC S) and flow cytometry. .
- Magnetic Cell Sorting Magnetic Cell Sorting
- ⁇ T cells can be efficiently proliferated.
- the cells obtained by the culture method of the present invention are collected by centrifugation or the like.
- the washing solution is preferably an isotonic solution having an osmotic pressure equal to that of cells, and more preferably a liquid that can be used as a pharmaceutical product.
- physiological saline PBS ( ⁇ hosphatebuferfelineseline; phosphate buffered saline), or the like.
- the r 3 ⁇ cells obtained after washing are collected using a centrifugal method, etc., and suspended in a liquid that can be used as a medicine, such as physiological saline, to prepare the therapeutic / preventive agent of the present invention. can do.
- a liquid that can be used as a medicine such as physiological saline
- the amount of the suspension liquid used is appropriately adjusted according to the number of cells to be administered and the administration method.
- the number of r (5 ⁇ cells used in the therapeutic / prophylactic agent of the present invention is appropriately selected according to the administration method, the type of disease, the symptom of the patient, etc., but is usually 10 8 to 10 12 Z. More preferably, it is 10 9 or more.
- cytokines such as 1 to 2 and 1 to 1 2
- the prevention and treatment agent of the present invention it is also possible to combine cytokines such as 1 to 2 and 1 to 1 2 with the prevention and treatment agent of the present invention.
- interferon interferon
- prophylactic / therapeutic agent when used as a therapeutic / preventive agent for viral infections, it is possible to combine the interferon (IFN-r) and the like with the prophylactic / therapeutic agent of the present invention.
- a method of administration for example, it may be injected intravenously, intradermally, subcutaneously, etc., may be directly injected into the affected area, or may be administered systemically as an instillation. Furthermore, it may be injected from an artery near the lesion.
- the therapeutic / prophylactic agent of the present invention has a high content of T ⁇ 5 T cells having non-specific cytotoxic function, cancer antigen-specific cytotoxic function or both cytotoxic functions, In particular, it contains many CD 56 positive r ⁇ ⁇ cells with high cytotoxic function, so it has the ability to specifically attack cancer cells or infected cells without attacking normal cells. It is an effective treatment and prevention agent for the treatment of cancer types and infectious diseases.
- the ⁇ 5 cells are derived from autologous lymphocytes, they can function without being excluded by the patient's own immune system when administered to the patient.
- Example 1
- AIM-V a culture solution AIM-V (hereinafter referred to as AIM-V (10 FCS)) to which FCS was added at 10%.
- I L-2 was added at a concentration of 400,
- the culture solution AIMV was added and cultured for 14 days.
- the percentage of cells expressing ⁇ 5 T cells in the cell group obtained after 14 days of culture was determined as the fluorescence—Ac tivated C It was measured by ell Sorter (hereinafter referred to as FAC S, Epics XL-MCL ADC, Beckman Cole Yuichi). The values obtained by measurement are shown in Tables 1 to 3 below.
- the concentration of bisphosphonate bone metabolism-improving drug should be 0 ⁇ 1 to 30 ⁇ , and IL-1 should be added to 400 to 200 OUZmL. It was confirmed that it was preferable. Further, it was confirmed that Ar ed i a is preferably added at a concentration of 1 to 30 ⁇ , On c l a st at a concentration of 1 to 30 / iM, and Zome t a at a concentration of 0.1 to 10 M. Table 1:% of T cells contained in mononuclear cells in which the concentration of IL-12 was changed when Ar e dia was used as the bisphosphonate (%)
- Peripheral blood was collected from healthy individuals, and peripheral blood mononuclear cells were separated using a specific gravity solution for blood cell separation.
- peripheral blood mononuclear cells obtained in 1) were suspended in the culture medium AIMV (10% FCS).
- Ardia was added to the peripheral blood mononuclear cell suspension to a concentration of 10 M.
- IL 1 was added so that the concentration of IL-1 was 20 00, 40 0, 700, 1 000 and 1 50 OUZmL.
- Table 4 and Table 5 show the percentage (%) of 5 ⁇ cells when the amount of IL-2 is changed.
- Table 4 shows the number of cells on days 7, 9, 1 and 14 and Table 5 shows the number of cells on days 0, 3, 7, 9, 1 and 14 (X 1 0 6 ) respectively.
- peripheral blood mononuclear cells in Table 4 a) and Table 5 a) are derived from the same donor.
- the peripheral blood mononuclear cells in Tables 4b) and 5b) are from the same donor. From these results, it was confirmed that the amount of IL-12 is preferably 400-1500 UZmL and the number of culture days is 11 days or more in order to obtain high purity and large amount of ⁇ cells.
- Table 4 A ratio of ⁇ 5 T cells when the amount of IL-12 is changed ()
- peripheral blood mononuclear cells were separated using a specific gravity solution for blood cell separation.
- IL-2 was added to a concentration of 700 U / mL. Furthermore, according to the proliferation of the cells, the culture solution A I M-V was added and cultured for 14 days.
- ⁇ cells activated and / or expanded by adding A redia to peripheral blood mononuclear cells express NKG2D.
- ⁇ KG 2 D is an active NK cell receptor that is expressed on NK cells, ⁇ 6 T cells and CD 8 positive T cells and expresses its ligand, MI CAZB molecule.
- Cells are known to be injured through NKG 2DZM ICA interaction.
- EZT ratio ratio of reaction cells to target cells
- An n + indicates the number of cells that have developed the fluorescence of Anne x i n V, and An n ⁇ indicates the number of cells that have not developed color.
- 7 AAD + indicates the number of cells that developed 7-AAD fluorescence, and 7 AAD- indicates the number of cells that did not. That is, An n-7 AAD + is a necrotic cell, An n + 7 AAD + is a late apoptotic cell, An n + 7 AAD- is an early apoptotic cell, Ann-7 AAD- Indicates that the cell is alive.
- CD 56-positive ⁇ ⁇ cells have higher cytotoxic activity against U 2 66 than CD 56-negative ⁇ ⁇ cells.
- the expression of NKG 2 D was also confirmed in CD 56 negative ⁇ ⁇ cells, confirming that ⁇ ⁇ cells expressing both NKG2D and CD 56 have more efficient cytotoxic activity. It was.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006529212A JPWO2006006720A1 (ja) | 2004-07-13 | 2005-07-12 | γδT細胞の培養方法、γδT細胞及び治療・予防剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-233922 | 2004-07-13 | ||
JP2004233922 | 2004-07-13 | ||
JP2005033616 | 2005-01-13 | ||
JP2005-033616 | 2005-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006006720A1 true WO2006006720A1 (ja) | 2006-01-19 |
Family
ID=35784045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/013218 WO2006006720A1 (ja) | 2004-07-13 | 2005-07-12 | γδT細胞の培養方法、γδT細胞及び治療・予防剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2006006720A1 (ja) |
WO (1) | WO2006006720A1 (ja) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008152822A1 (ja) * | 2007-06-15 | 2008-12-18 | Medinet Co., Ltd. | 医薬 |
WO2010001599A1 (ja) | 2008-07-01 | 2010-01-07 | 株式会社メディネット | CTLとγδT細胞の同時誘導方法 |
JPWO2008111430A1 (ja) * | 2007-03-09 | 2010-06-24 | タカラバイオ株式会社 | γδT細胞集団の製造方法 |
US7749760B2 (en) | 2008-07-10 | 2010-07-06 | Hyogo College Of Medicine | Vγ9Vδ2 T cell proliferation agent, method for producing activated Vγ9Vδ2 T cells, and uses thereof |
WO2011096504A1 (ja) * | 2010-02-08 | 2011-08-11 | 株式会社日本バイオセラピー研究所 | Nk細胞強化型血液製剤の製造方法 |
WO2012099093A1 (ja) * | 2011-01-21 | 2012-07-26 | 株式会社日本バイオセラピー研究所 | Nk細胞強化型血液製剤の製造方法 |
JP2013081428A (ja) * | 2011-10-11 | 2013-05-09 | Biotherapy Institute Of Japan | Cd56陽性t細胞増強方法 |
CN104293734A (zh) * | 2014-09-28 | 2015-01-21 | 上海云舜生物技术有限公司 | 一种人γδT细胞的制备方法 |
CN104651308A (zh) * | 2013-11-22 | 2015-05-27 | 深圳先进技术研究院 | 一种用磷酸盐扩增γδT细胞的方法及其应用 |
WO2016005752A1 (en) | 2014-07-09 | 2016-01-14 | Tc Biopharm Ltd | Gamma delta t cells and uses thereof |
WO2016060111A1 (ja) * | 2014-10-14 | 2016-04-21 | 学校法人 聖マリアンナ医科大学 | γδT細胞の製造方法および医薬 |
WO2016166544A1 (en) | 2015-04-15 | 2016-10-20 | Tc Biopharm Ltd | Modified gamma delta cells and uses thereof |
CN106795493A (zh) * | 2014-10-06 | 2017-05-31 | 堤乐哈修门医学研究基础建设及服务有限公司 | 使用双膦酸盐、抗cd3抗体和il‑2扩增t细胞群体 |
WO2018143243A1 (ja) * | 2017-02-03 | 2018-08-09 | 国立大学法人神戸大学 | 人工多能性幹細胞の作製方法 |
WO2020013315A1 (ja) | 2018-07-13 | 2020-01-16 | 国立大学法人京都大学 | γδT細胞の製造方法 |
JP2020506713A (ja) * | 2017-02-07 | 2020-03-05 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 多能性幹細胞から模倣自然免疫細胞を生成する方法及びキット |
WO2021085504A1 (ja) | 2019-11-01 | 2021-05-06 | 京都府公立大学法人 | B細胞抗体受容体、及びその利用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201421716D0 (en) * | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045429A2 (en) * | 2001-11-28 | 2003-06-05 | Novartis Ag | Anti-t cell immunotoxin fusion protein and its therapeutic use |
WO2003070921A1 (fr) * | 2002-02-22 | 2003-08-28 | Innate Pharma | PROCÉDÉS DE PRODUCTION DE LYMPHOCYTES ϜδT |
WO2005021708A2 (en) * | 2003-05-16 | 2005-03-10 | University Of Maryland Biotechnology Institute | Bisphosphonates for prophylaxis and therapy against bioterrorism agents |
-
2005
- 2005-07-12 JP JP2006529212A patent/JPWO2006006720A1/ja active Pending
- 2005-07-12 WO PCT/JP2005/013218 patent/WO2006006720A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045429A2 (en) * | 2001-11-28 | 2003-06-05 | Novartis Ag | Anti-t cell immunotoxin fusion protein and its therapeutic use |
WO2003070921A1 (fr) * | 2002-02-22 | 2003-08-28 | Innate Pharma | PROCÉDÉS DE PRODUCTION DE LYMPHOCYTES ϜδT |
WO2005021708A2 (en) * | 2003-05-16 | 2005-03-10 | University Of Maryland Biotechnology Institute | Bisphosphonates for prophylaxis and therapy against bioterrorism agents |
Non-Patent Citations (2)
Title |
---|
KUNZMANN V. ET AL: "Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.", BLOOD., vol. 96, no. 2, 2000, pages 384 - 392, XP002276947 * |
THOMPSON K. ET AL: "Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.", JOURNAL OF BONE AND MINERAL RESEARCH., vol. 19, no. 2, February 2004 (2004-02-01), pages 278 - 288, XP002993068 * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013176403A (ja) * | 2007-03-09 | 2013-09-09 | Takara Bio Inc | γδT細胞集団の製造方法 |
JPWO2008111430A1 (ja) * | 2007-03-09 | 2010-06-24 | タカラバイオ株式会社 | γδT細胞集団の製造方法 |
WO2008152822A1 (ja) * | 2007-06-15 | 2008-12-18 | Medinet Co., Ltd. | 医薬 |
JPWO2008152822A1 (ja) * | 2007-06-15 | 2010-08-26 | 株式会社メディネット | 医薬 |
WO2010001599A1 (ja) | 2008-07-01 | 2010-01-07 | 株式会社メディネット | CTLとγδT細胞の同時誘導方法 |
US8962313B2 (en) | 2008-07-01 | 2015-02-24 | Medinet Co., Ltd. | Method for the simultaneous induction of CTL and γδT cell |
CN102137925B (zh) * | 2008-07-01 | 2014-12-10 | 迈世耐特股份公司 | 同时诱导CTL和γδT细胞的方法 |
JP5524056B2 (ja) * | 2008-07-01 | 2014-06-18 | 株式会社メディネット | CTLとγδT細胞の同時誘導方法 |
US7749760B2 (en) | 2008-07-10 | 2010-07-06 | Hyogo College Of Medicine | Vγ9Vδ2 T cell proliferation agent, method for producing activated Vγ9Vδ2 T cells, and uses thereof |
JP5766619B2 (ja) * | 2010-02-08 | 2015-08-19 | 株式会社日本バイオセラピー研究所 | Nk細胞強化型血液製剤の製造方法 |
WO2011096504A1 (ja) * | 2010-02-08 | 2011-08-11 | 株式会社日本バイオセラピー研究所 | Nk細胞強化型血液製剤の製造方法 |
JPWO2012099093A1 (ja) * | 2011-01-21 | 2014-06-30 | 株式会社日本バイオセラピー研究所 | Nk細胞強化型血液製剤の製造方法 |
WO2012099093A1 (ja) * | 2011-01-21 | 2012-07-26 | 株式会社日本バイオセラピー研究所 | Nk細胞強化型血液製剤の製造方法 |
JP2013081428A (ja) * | 2011-10-11 | 2013-05-09 | Biotherapy Institute Of Japan | Cd56陽性t細胞増強方法 |
CN104651308A (zh) * | 2013-11-22 | 2015-05-27 | 深圳先进技术研究院 | 一种用磷酸盐扩增γδT细胞的方法及其应用 |
WO2016005752A1 (en) | 2014-07-09 | 2016-01-14 | Tc Biopharm Ltd | Gamma delta t cells and uses thereof |
CN104293734A (zh) * | 2014-09-28 | 2015-01-21 | 上海云舜生物技术有限公司 | 一种人γδT细胞的制备方法 |
CN104293734B (zh) * | 2014-09-28 | 2018-01-09 | 上海云舜生物技术有限公司 | 一种人γδT细胞的制备方法 |
CN106795493A (zh) * | 2014-10-06 | 2017-05-31 | 堤乐哈修门医学研究基础建设及服务有限公司 | 使用双膦酸盐、抗cd3抗体和il‑2扩增t细胞群体 |
WO2016060111A1 (ja) * | 2014-10-14 | 2016-04-21 | 学校法人 聖マリアンナ医科大学 | γδT細胞の製造方法および医薬 |
WO2016166544A1 (en) | 2015-04-15 | 2016-10-20 | Tc Biopharm Ltd | Modified gamma delta cells and uses thereof |
WO2018143243A1 (ja) * | 2017-02-03 | 2018-08-09 | 国立大学法人神戸大学 | 人工多能性幹細胞の作製方法 |
JPWO2018143243A1 (ja) * | 2017-02-03 | 2019-11-21 | 国立大学法人神戸大学 | 人工多能性幹細胞の作製方法 |
US20200017837A1 (en) * | 2017-02-03 | 2020-01-16 | National University Corporation Kobe University | Method For Producing Induced Pluripotent Stem Cells |
JP7224021B2 (ja) | 2017-02-03 | 2023-02-17 | 国立大学法人神戸大学 | 人工多能性幹細胞の作製方法 |
JP2020506713A (ja) * | 2017-02-07 | 2020-03-05 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 多能性幹細胞から模倣自然免疫細胞を生成する方法及びキット |
JP7092281B2 (ja) | 2017-02-07 | 2022-06-28 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 多能性幹細胞から模倣自然免疫細胞を生成する方法及びキット |
WO2020013315A1 (ja) | 2018-07-13 | 2020-01-16 | 国立大学法人京都大学 | γδT細胞の製造方法 |
KR20210030373A (ko) | 2018-07-13 | 2021-03-17 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | γδT 세포를 제조하는 방법 |
WO2021085504A1 (ja) | 2019-11-01 | 2021-05-06 | 京都府公立大学法人 | B細胞抗体受容体、及びその利用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006006720A1 (ja) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006006720A1 (ja) | γδT細胞の培養方法、γδT細胞及び治療・予防剤 | |
JP5384827B2 (ja) | 抗原提示細胞の活性化処理方法 | |
JP5524056B2 (ja) | CTLとγδT細胞の同時誘導方法 | |
US9834753B2 (en) | Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same | |
US20190175650A1 (en) | METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES | |
JP5816627B2 (ja) | 抗原特異的t細胞の増殖のための方法 | |
JP5792622B2 (ja) | ナチュラルキラー細胞の製造方法 | |
EP2606125B1 (en) | Cells expressing th1 characteristics and cytolytic properties | |
JP5825966B2 (ja) | Cd56陽性t細胞増強方法 | |
CN113980901B (zh) | 一种制备高纯度的成熟人树突状细胞的方法及应用 | |
JP2010259373A (ja) | 抗原提示細胞の活性化処理方法 | |
JP2012090574A (ja) | γδT細胞の製造方法および医薬 | |
Hu et al. | HPV16 CTL epitope peptide-activated dendritic cell and natural killer co-culture for therapy of cervical cancer in an animal model | |
US20060073589A1 (en) | Rapid generation of activated mononuclear antigen presenting cells from monocytes | |
JP2004248504A (ja) | Th2型またはTh1型にシフトしたナチュラルキラーT細胞の増幅方法 | |
JPWO2008129874A1 (ja) | 腫瘍細胞の標的化方法、及びその用途 | |
JP2001026545A (ja) | 免疫応答活性化製剤 | |
TW200831670A (en) | Methods for the cultivation of tumor cells and application of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006529212 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |